A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Protective effect of synbiotic combination of Lactobacillus plantarum SC-5 and olive oil extract tyrosol in a murine model of ulcerative colitis
Journal of Translational Medicine Open Access 25 March 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Danese, S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61, 918–932 (2012).
Almradi, A. et al. Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease. BioDrugs 34, 713–721 (2020).
Danese, S., Vuitton, L. & Peyrin-Biroulet, L. Biologic agents for IBD: practical insights. Nat. Rev. Gastroenterol. Hepatol. 12, 537–545 (2015).
Roda, G., Jharap, B., Neeraj, N. & Colombel, J.-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl Gastroenterol. 7, e135 (2016).
Hanžel, J. & D’Haens, G. R. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin. Biol. Ther. 20, 399–406 (2020).
Parigi, T. L., Iacucci, M. & Ghosh, S. Blockade of IL-23: what is in the pipeline? J. Crohns Colitis 16 (Suppl. 2), ii64–ii72 (2022).
Noviello, D. et al. The IL23-IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges. Front. Immunol. 12, 611256 (2021).
Verstockt, B. et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20, 433–446 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.D. has served as a speaker, consultant and advisory board member for Schering Plough, Abbott (AbbVie) Laboratories, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, AstraZeneca, Novo Nordisk, Vifor and Johnson and Johnson. L.P.-B. has served as consultant for Merck, AbbVie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Biogaran, Boehringer-Ingelheim, Lilly, Pfizer, Jndex Pharmaceuticals, Amgen, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestlé, Enterome, Mylan, HAC-Pharma and Tigenix, and has served as speaker for Merck, AbbVie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Boehringer-Ingelheim, Pfizer, Amgen, Biogen and Samsung Bioepis.
Additional information
Related links
NCT03466411: https://clinicaltrials.gov/study/NCT03466411
NCT03926130: https://clinicaltrials.gov/study/NCT03926130
NCT04524611: https://www.clinicaltrials.gov/study/NCT04524611
Supplementary information
Rights and permissions
About this article
Cite this article
Danese, S., Peyrin-Biroulet, L. Are all the IL-23 blockers the same in inflammatory bowel disease?. Nat Rev Gastroenterol Hepatol 21, 138–139 (2024). https://doi.org/10.1038/s41575-023-00889-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00889-7
This article is cited by
-
Protective effect of synbiotic combination of Lactobacillus plantarum SC-5 and olive oil extract tyrosol in a murine model of ulcerative colitis
Journal of Translational Medicine (2024)
